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:   western blot

1. INTRODUCTION {#cas14037-sec-0001}
===============

Hepatocellular carcinoma is the sixth most common cancer and the third leading cause of cancer‐related mortality worldwide.[1](#cas14037-bib-0001){ref-type="ref"} Although some progress has been made in basic and clinical research on HCC, including identification of several diagnostic markers and detection of some genes related to the invasion and metastasis of HCC,[2](#cas14037-bib-0002){ref-type="ref"} the underlying mechanism of HCC remains to be determined.[3](#cas14037-bib-0003){ref-type="ref"}, [4](#cas14037-bib-0004){ref-type="ref"}

Lymphoid‐specific helicase belongs to the SNF2 family of chromatin‐remodeling ATPases and plays a critical role in maintaining DNA methylation in development in plants and mammals.[5](#cas14037-bib-0005){ref-type="ref"}, [6](#cas14037-bib-0006){ref-type="ref"}, [7](#cas14037-bib-0007){ref-type="ref"}, [8](#cas14037-bib-0008){ref-type="ref"} Recently, LSH has been identified as one of 5‐hydroxymethylcytosine (5‐hmC) readers in mouse embryonic stem cells, neuronal progenitor cells, and adult mouse brain.[9](#cas14037-bib-0009){ref-type="ref"} Interestingly, LSH maintained genome stability in mammalian somatic cells and also served as a driver in several cancers.[10](#cas14037-bib-0010){ref-type="ref"}, [11](#cas14037-bib-0011){ref-type="ref"}, [12](#cas14037-bib-0012){ref-type="ref"}, [13](#cas14037-bib-0013){ref-type="ref"}, [14](#cas14037-bib-0014){ref-type="ref"}, [15](#cas14037-bib-0015){ref-type="ref"} However, its role in the progression of HCC remains to be determined.

In the present study, we examined the role of LSH in the growth, invasion and metastasis of HCC cells. We also explored the mechanisms of transcription regulation of LSH. We finally established the relationship between LSH expression and HCC prognosis.

2. MATERIALS AND METHODS {#cas14037-sec-0002}
========================

2.1. Cell lines and cell culture {#cas14037-sec-0003}
--------------------------------

Human HCC cell lines HCCLM3 (established by the Liver Cancer Institute, Zhongshan Hospital, Fudan University), Huh7, PLC/PRF/5, and Hep3B (purchased from ATCC and raised in Liver Cancer Institute, Zhongshan Hospital, Fudan University) were used in this study. Hep3B cells were cultured in DMEM (HyClone, Logan, UT, USA). HCCLM3, Huh‐7, and PLC/PRF/5 cell lines were cultured in DMEM containing 10% FBS (YEASEN, Shanghai, China) supplemented with 100 IU/mL penicillin and 100 μg/mL streptomycin. All cell lines were incubated at 37°C in a humidified atmosphere with 5% CO~2~. All cell culture media and FBS were obtained from Gibco (Invitrogen, Carlsbad, CA, USA). Other supplies were obtained from Corning (Corning, NY, USA). This study was approved by the Ethics Committee at Zhongshan Hospital of Fudan University. Full informed consent was obtained from all patients.

2.2. Quantitative real‐time polymerase chain reaction and western blot {#cas14037-sec-0004}
----------------------------------------------------------------------

Quantitative real‐time polymerase chain reaction and WB were carried out as previously described.[16](#cas14037-bib-0016){ref-type="ref"} Primary antibodies against CENPF (20982‐1‐AP) and LSH (11955‐1‐AP) were purchased from Proteintech (Chicago, IL, USA). Sequences (5′‐3′) of primers used for qPCR are listed below.

Lymphoid‐specific helicase, forward primer GAGGCTCCAGCAATGGTTGAA, reverse primer CGCTCTCTCTCTAGTCCAGCA. CENPF, forward primer CTCTCCCGTCAACAGCGTTC, reverse primer GTTGTGCATATTCTTGGCTTGC.

Sequences (5′‐3′) of primers used for ChIP‐qPCR are listed below.

CENPF, forward primer TCTGCTCGGGTTCAAACTGG, reverse primer TGTGAGTCCGTGACCGAGTA.

2.3. Transfection and clone selection {#cas14037-sec-0005}
-------------------------------------

Lymphoid‐specific helicase, LSH‐shRNA, and CENPF‐shRNA expression lentiviral vectors were purchased from Shanghai GeneChem Co. (Shanghai, China), and the lentiviral vector was transfected using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA), according to the manufacturer\'s instructions. Transfected HCC cells were selected using puromycin for 7 days prior to assay.

2.4. Patients and follow up {#cas14037-sec-0006}
---------------------------

Fresh tissues were randomly collected from consecutive patients with HCC who underwent curative resection between 2005 and 2009 at the Institute of Liver Cancer, Fudan University. None of the patients received any chemotherapy or radiation treatment prior to the surgery. The study and methods for informed consent were examined and certified by the Ethics Committee of Fudan University.

2.5. Immunohistochemistry and tissue microarrays {#cas14037-sec-0007}
------------------------------------------------

Immunohistochemistry was carried out as described elsewhere.[16](#cas14037-bib-0016){ref-type="ref"} Tissue microarrays (TMA) were constructed as previously described.[17](#cas14037-bib-0017){ref-type="ref"} Primary antibodies against CENPF (20982‐1‐AP) and LSH (11955‐1‐AP) were obtained from Proteintech.

2.6. Cell migration, Matrigel invasion assay, cell viability, and colony formation assay {#cas14037-sec-0008}
----------------------------------------------------------------------------------------

Cell migration was tested by wound‐healing experiment. Matrigel invasion assay was obtained from BD Biosciences (Franklin Lakes, NJ, USA). Cell viability was measured by CCK‐8 assay (YEASEN, Shanghai, China). Matrigel invasion assay and CCK‐8 assay were carried out according to the manufacturers' protocols. Colony formation assay and wound‐healing experiment were done as previously described.[16](#cas14037-bib-0016){ref-type="ref"}

2.7. Flow cytometry assay {#cas14037-sec-0009}
-------------------------

Cell cycle and apoptosis were detected by flow cytometry (FCM; Becton Dickinson, Franklin Lakes, NJ, USA).

2.8. Tumor xenograft assay {#cas14037-sec-0010}
--------------------------

Hepatocellular carcinoma cells were used to establish s.c. xenograft tumor models. Tumor growth was monitored twice weekly, and mice were killed after 4 weeks. Tumors were measured in two dimensions.

2.9. Chromatin immunoprecipitation {#cas14037-sec-0011}
----------------------------------

Chromatin immunoprecipitation was carried out as follows. Briefly, DNA was cross‐linked using 1% formalin, the cells were lysed in SDS buffer, and DNA was fragmented by sonication. ChIP for LSH was done using an anti‐Flag antibody (SAB4301135; Sigma Chemical Co., St Louis, MO, USA).

2.10. High‐throughput sequencing {#cas14037-sec-0012}
--------------------------------

The resulting DNA library was sequenced on Illumina Hiseq2500 (San Diego, CA, USA). The results obtained were analyzed using Hisat2, StringTie and Ballgown tools to obtain deferentially expressed genes. The UCSC Genome Browser (University of California, Santa Cruz) was used for data visualization.

2.11. Statistical analysis {#cas14037-sec-0013}
--------------------------

Statistical analysis was carried out using SPSS software (version 19.0; SPSS, Inc.). Values are expressed as mean and standard deviation (SD). Student\'s *t* test and one‐way ANOVA were used for comparisons between groups. Categorical data were analyzed by chi‐squared or Fisher\'s exact tests. Correlation analysis was carried out to assess the relationship between LSH and CENPF expression. Cumulative recurrence and survival rates were analyzed using Kaplan‐Meier\'s method and log‐rank test. Cox\'s proportional hazards regression model was used to analyze independent prognostic factors. *P *\<* *0.05 was considered statistically significant.

3. RESULTS {#cas14037-sec-0014}
==========

3.1. Lymphoid‐specific helicase is overexpressed in tumor tissues and its expression correlates with overall survival of HCC patients {#cas14037-sec-0015}
-------------------------------------------------------------------------------------------------------------------------------------

To explore the expression and potential role of LSH in HCC, we first used the publicly available HCC database (GEPIA, <http://gepia.cancer-pku.cn>) to analyze LSH mRNA expression between tumor specimens and normal tissues.[18](#cas14037-bib-0018){ref-type="ref"} As shown in Figure [1](#cas14037-fig-0001){ref-type="fig"}A, LSH mRNA expression was significantly elevated in HCC tissues compared to para‐tumor liver tissues. Importantly, LSH mRNA expression was negatively associated with overall survival (*P *=* *0.018, Figure [1](#cas14037-fig-0001){ref-type="fig"}B) and relapse‐free survival (*P *\< 0.001, Figure [1](#cas14037-fig-0001){ref-type="fig"}B), suggesting that LSH expression may be an indicator of the prognosis of HCC patients.

![Lymphoid‐specific helicase (LSH) is overexpressed in tumor tissues and its expression correlates with overall survival of hepatocellular carcinoma (HCC) patients. A, Results from public database GEPIA indicated LSH expression in HCC is higher than that in para‐tumor tissues. B, Online analysis of overall survival (OS) and disease‐free survival (DFS) shows that higher LSH expression indicates a poorer prognosis. *P*‐values are shown in the figure. C and D, mRNA and protein expressions of LSH were tested by qPCR and western blot. E, HCC tissue microarrays were tested by immunohistochemistry (IHC) using LSH antibody. F, IHC scores of LSH were analyzed for OS and DFS. \**P *\< 0.05](CAS-110-2133-g001){#cas14037-fig-0001}

Lymphoid‐specific helicase expression was significantly higher in tumor tissues than in para‐tumor tissues (Figure [1](#cas14037-fig-0001){ref-type="fig"}C,D). To validate the relationship between LSH expression and the prognosis of HCC patients, 208 HCC tissues and corresponding para‐tumor liver tissues were subjected to IHC staining for LSH. Positive staining was located in the nucleus of tumor cells (Figure [1](#cas14037-fig-0001){ref-type="fig"}E). We further analyzed the correlation between LSH expression and clinical features, as shown in Table [1](#cas14037-tbl-0001){ref-type="table"}. Furthermore, Kaplan‐Meier analysis showed that higher level of LSH expression was associated with shorter overall survival (OS) (*P *\<* *0.001; Figure [1](#cas14037-fig-0001){ref-type="fig"}F) and disease‐free survival (DFS) (*P *\<* *0.001; Figure [1](#cas14037-fig-0001){ref-type="fig"}F). Moreover, univariate and multivariate analyses showed that LSH expression was an independent prognostic factor of OS for patients with HCC (*P *=* *0.001; Table [2](#cas14037-tbl-0002){ref-type="table"}). Taken together, these data indicate that upregulation of LSH contributes to recurrence and is associated with a poorer prognosis in HCC.

###### 

Correlation between LSH expression and clinicopathological characteristics in 208 HCC patients

  Variable                No. of patients   LSH expression   *P*‐value   
  ----------------------- ----------------- ---------------- ----------- -------------
  Gender                                                                 
   Female                 30                11               19          0.064
   Male                   178               57               121         
  Age (years)                                                            
   \<52                   110               39               71          0.135
   ≥52                    98                39               59          
  Cirrhosis                                                              
   Yes                    186               72               114         **\<0.001**
   No                     22                6                16          
  HBsAg                                                                  
   Positive               36                14               22          0.028
   Negative               172               64               108         
  HCV                                                                    
   Positive               6                 1                5           0.190
   Negative               202               77               125         
  AFP (ng/mL)                                                            
   \<20                   77                30               47          0.755
   ≥20                    131               48               83          
  Tumor size (cm)                                                        
   \<5                    116               50               66          **\<0.001**
   ≥5                     92                28               64          
  No. tumors                                                             
   Single                 174               68               106         **\<0.001**
   Multiple               34                10               24          
  Tumor encapsulation                                                    
   Complete               102               43               59          0.023
   None                   106               35               71          
  Tumor differentiation                                                  
   I + II                 151               56               95          **\<0.001**
   III + IV               57                22               35          
  Tumor thrombus                                                         
   Positive               133               66               67          **\<0.001**
   Negative               75                12               63          
  TNM stage                                                              
   I                      147               58               89          **\<0.001**
   II + III               61                20               41          

Bold values are statistically significant (*P *\<* *0.05).

AFP, alpha fetoprotein; HBsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; LSH, lymphoid‐specific helicase.

John Wiley & Sons, Ltd

###### 

Univariate and multivariate analyses of factors associated with overall survival

  Factor                                   Univariate *P*‐value   Multivariate analysis                 
  ---------------------------------------- ---------------------- ----------------------- ------------- -----------
  Gender (female vs male)                  0.173                                                        NA
  Age (years) (≥52 vs \<52)                0.381                                                        NA
  Liver cirrhosis (yes vs no)              0.843                                                        NA
  HBsAg (positive vs negative)             0.167                                                        NA
  HCV (positive vs negative)               0.981                                                        NA
  Serum AFP, ng/mL (≥20 vs \<20)           0.371                                                        NA
  Tumor encapsulation (yes vs no)          0.534                                                        NA
  Tumor differentiation (III/IV vs I/II)   0.193                                                        NA
  Tumor number (multiple vs single)        0.074                                                        NA
  Tumor thrombus (positive vs negative)    **0.003**              1.729                   1.138‐2.191   **0.001**
  Tumor size (diameter, cm) (≥5 vs \<5)    **0.001**              1.942                   1.276‐2.334   **0.003**
  TNM stage (I/II vs III/IV)               0.021                                                        NA
  LSH expression (high vs low)             **\<0.001**            2.115                   1.562‐3.156   **0.001**
  CENPF expression (high vs low)           **\<0.001**            2.225                   1.361‐3.638   **0.001**

Multivariate analysis, Cox proportional hazards regression model. Variables were adopted for their prognostic significance by univariate analysis with forward stepwise selection (forward, likelihood ratio). Variables were adopted for their prognostic significance by univariate analysis (*P* \< 0.01). Bold indicates *P* \< 0.05.

AFP, alpha fetoprotein; CENPF, centromere protein F; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; HR, hazard ratio; LSH, lymphoid‐specific helicase; NA, not applicable.

John Wiley & Sons, Ltd

3.2. Knockdown of LSH expression inhibits cell growth and invasion of HCC cells in vitro and in vivo {#cas14037-sec-0016}
----------------------------------------------------------------------------------------------------

To further explore the function of LSH in HCC, we analyzed its expression in four different metastatic potential HCC cell lines to select the most appropriate cell models for loss‐of‐function and gain‐of‐function assays (Figure [2](#cas14037-fig-0002){ref-type="fig"}A). Results showed that high metastatic potential HCC cell lines LCCLM3 and Huh‐7 tended to express a high level of LSH, whereas low metastatic potential HCC cell lines PLC/PRF/5 and Hep3B had low LSH expression (Figure [2](#cas14037-fig-0002){ref-type="fig"}A). Then, we successfully constructed HCCLM3 cells with stable knocked‐down LSH (HCCLM3‐shLSH) and PLC/PRF/5 cells with upregulated LSH expression (PLC/PRF/5‐LSH), confirmed by WB and qPCR (Figure [2](#cas14037-fig-0002){ref-type="fig"}B).

![Knockdown of lymphoid‐specific helicase (LSH) expression inhibits cell growth and invasion of hepatocellular carcinoma (HCC) cells in vitro and in vivo. A, Western blot (WB) and qPCR experiments for testing LSH in HCC cell lines. B, Knockdown and overexpression of LSH confirmed by WB and qPCR. C, CCK‐8 assays show decreased OD450 after LSH knockdown and elevated OD450 after overexpression. D, Colony formation assays for the HCC cell lines used above. E and F, Cell cycle and apoptosis rates tested by flow cytometry. G, Transwell assay carried out in these cell lines. H and I, Results of wound‐healing experiments. J and K, Subcutaneous tumors in nude mice after death. \**P* \< 0.05, \*\**P* \< 0.01](CAS-110-2133-g002){#cas14037-fig-0002}

CCK‐8 assay showed that cell proliferation was significantly decreased in LSH knockdown cells (Figure [2](#cas14037-fig-0002){ref-type="fig"}C). The capacity for colony formation of HCC cells was clearly reduced after LSH was knocked down, whereas the capacity for colony formation was enhanced when LSH was overexpressed (Figure [2](#cas14037-fig-0002){ref-type="fig"}D). Flow cytometry analyses showed that the proportion of cells in G0/G1 in HCCLM3 cells was higher than that of HCCLM3‐shLSH and vice versa (Figure [2](#cas14037-fig-0002){ref-type="fig"}E). Similarly, downregulated expression of LSH reduced the increased rate of apoptosis (Figure [2](#cas14037-fig-0002){ref-type="fig"}F). Invasion capacity was also inhibited in LSH knockdown cells and enhanced in cells overexpressing LSH (Figure [2](#cas14037-fig-0002){ref-type="fig"}G). Wound healing assay showed that the migratory ability of HCC cells was significantly inhibited after LSH expression was decreased (Figure [2](#cas14037-fig-0002){ref-type="fig"}H,I).

In an in vivo experiment, 5 × 10^6^ HCCLM3‐shLSH, PLC/PRF/5‐LSH cells and controls were s.c. implanted into nude mice, respectively. Mice were killed on the 35th day after inoculation. The results showed that xenografts from HCCLM3 cells and PLC/PRF/5‐LSH cells were significantly bigger than those from HCCLM3‐shLSH and PLC/PRF/5 cells, respectively (Figure [2](#cas14037-fig-0002){ref-type="fig"}J,K). Together, these findings indicate that LSH effectively promotes the growth and invasion of HCC cells.

3.3. mRNA sequencing and ChIP‐seq show target genes of LSH {#cas14037-sec-0017}
----------------------------------------------------------

To further investigate the molecular mechanism of the role of LSH in HCC cells, we used mRNA‐seq and ChIP‐seq to analyze mRNA expression profiles of alteration of LSH expression and DNA‐protein interactions with LSH, respectively. First, gene expression profiles of HCCLM3 cells stably transfected with two different shRNA sequences were analyzed by mRNA‐seq, and the differentially expressed genes (\>2‐fold) were identified (shown in heat map, Figure [3](#cas14037-fig-0003){ref-type="fig"}A). We found that 4342 differentially expressed genes overlapped in these two cells. Then, we used to ChIP for LSH and sequence to identify the target genes of LSH in the above HCCLM3 cells transfected with two different shRNA sequences. We identified 1238 differentially expressed genes (\>2‐fold) and they intersected with the above 4342 overlapped differential genes. Results showed 146 overlapping genes (Figure [3](#cas14037-fig-0003){ref-type="fig"}B). KEGG and gene ontology (GO) analyses for these 146 genes were carried out. The results showed that cell biological pathways, such as cell cycle, division, and response to drugs and hormones were increased (Figure [3](#cas14037-fig-0003){ref-type="fig"}B). Gene set enrichment analysis (GSEA) was carried out and significant pathways were identified for both up‐ and downregulated gene sets. As LSH is located mainly in the nucleus (Figure [1](#cas14037-fig-0001){ref-type="fig"}E), pathways related to chromosome, nuclear division and cell cycle were analyzed. Results showed knockdown of LSH obviously disrupted these pathways (Figure [3](#cas14037-fig-0003){ref-type="fig"}C). Of note, one of the genes most frequently included in these gene sets was CENPF (Figure [3](#cas14037-fig-0003){ref-type="fig"}D).

![mRNA sequencing (mRNA‐seq) and ChIP‐seq shows target genes of lymphoid‐specific helicase (LSH). A, Heat map of RNA‐seq after LSH knockdown. B, Gene ontology (GO) and KEQQ analysis of differential genes of RNA‐seq, ChIP‐seq and their overlap. C, Gene set enrichment analysis (GSEA) analysis of differential genes of RNA‐seq. D, Frequencies of included genes in GO and KEGG gene sets](CAS-110-2133-g003){#cas14037-fig-0003}

3.4. Centromere protein F is overexpressed in HCC tissues and is positively correlated with LSH protein overexpression {#cas14037-sec-0018}
----------------------------------------------------------------------------------------------------------------------

Given the important role of CENPF in the cell cycle, mitosis and regulation of PLK1 activity at G2/M transition, we further explored the interaction of LSH with CENPF. We first analyzed the relationship between LSH and CENPF expression in The Cancer Genome Atlas (TCGA) database. We observed that *LSH* and *Cenpf* mRNA were consistently upregulated in HCC tissues, compared to para‐tumor liver tissues (Figure [4](#cas14037-fig-0004){ref-type="fig"}A,B, Pearson 0.69, Spearman 0.8 by cBioPortal). Moreover, survival analysis showed that higher *Cenpf* expression in tumor tissues was associated with poorer prognosis in HCC patients (Figure [4](#cas14037-fig-0004){ref-type="fig"}C,D, by GEPIA).

![Centromere protein F (CENPF) is overexpressed in hepatocellular carcinoma (HCC) tissues and is positively correlated with lymphoid‐specific helicase (LSH) protein overexpression. A, CENPF and LSH mRNA expression. B, Correlation of mRNA level between CENPF and LSH. C and D, Online analysis for overall survival (OS) and disease‐free survival (DFS) shows that higher CENPF expression indicates a poorer prognosis. E, mRNA and protein levels tested by qPCR and western blot (WB). F, Immunohistochemistry (IHC) test of CENPF protein expression in clinical samples, and the correlation between LSH and CENPF expression. G, IHC scores of CENPF were analyzed for OS and DFS. H, OS and DFS analysis integrated CENPF and LSH IHC scores. \**P* \< 0.05. \*\*\**P* \< 0.001](CAS-110-2133-g004){#cas14037-fig-0004}

We also investigated the expression of CENPF in 208 HCC samples and analyzed the correlation between CENPF and LSH. Results showed that CENPF expression in tumor tissues was significantly higher than that in para‐tumor tissues at the level of mRNA and protein (Figure [4](#cas14037-fig-0004){ref-type="fig"}E). Importantly, we found that increased LSH protein level is associated with increased CENPF protein level (Figure [4](#cas14037-fig-0004){ref-type="fig"}F). Furthermore, survival analysis also showed that high CENPF expression in tumor tissues was associated with short overall survival (OS) (*P *\<* *0.001) and DFS (*P *\<* *0.001; Figure [4](#cas14037-fig-0004){ref-type="fig"}G). Similarly, univariate and multivariate analyses were carried out and showed that CENPF expression was an independent prognostic factor of OS for patients with HCC (*P *=* *0.001; Table [3](#cas14037-tbl-0003){ref-type="table"}).

###### 

Correlation between CENPF and clinicopathological characteristics in 208 HCC patients

  Variable                No. of patients   CENPF expression   *P*‐value   
  ----------------------- ----------------- ------------------ ----------- -------
  Gender                                                                   
   Female                 30                7                  23          0.214
   Male                   178               66                 112         
  Age (years)                                                              
   \<52                   98                35                 63          0.885
   ≥52                    110               38                 72          
  Hepatic cirrhosis                                                        
   Yes                    186               66                 120         0.817
   No                     22                7                  15          
  HBsAg                                                                    
   Positive               172               114                58          0.443
   Negative               36                21                 15          
  HCV                                                                      
   Positive               6                 3                  3           0.667
   Negative               202               132                70          
  AFP (ng/mL)                                                              
   \<20                   73                44                 29          0.654
   ≥20                    135               86                 49          
  Tumor size (cm)                                                          
   \<5                    116               73                 43          0.560
   ≥5                     92                62                 30          
  No. tumors                                                               
   Single                 174               110                64          0.327
   Multiple               34                25                 9           
  Tumor encapsulation                                                      
   Complete               102               41                 61          0.198
   None                   106               33                 73          
  Tumor differentiation                                                    
   I + II                 151               102                49          0.198
   III + IV               57                33                 24          
  Tumor thrombus                                                           
   Positive               64                40                 24          0.640
   Negative               144               95                 49          
  TNM stage                                                                
   I                      146               95                 51          0.017
   II + III               62                40                 22          

Bold values are statistically significant (*P *\<* *0.05).

AFP, alpha fetoprotein; CENPF, centromere protein F; HBsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma; HCV, hepatitis C virus.

John Wiley & Sons, Ltd

Considering the positive relationship between LSH and CENPF expression, we divided the cohorts into three subgroups based on the expression of LSH and CENPF (both high, both low, single high). We then carried out Kaplan‐Meier analysis and log‐rank test and found that HCC patients with high expression of both CENPF and LSH ("both high") showed the worst OS (*P *\<* *0.001) and DFS (*P *\<* *0.001), whereas the subgroup with low expression of both CENPF and LSH ("both low") had the best prognosis (Figure [4](#cas14037-fig-0004){ref-type="fig"}H). These clinical data indicate that LSH probably plays a substantial role in HCC in a CENPF‐dependent manner.

3.5. Lymphoid‐specific helicase binds to the transcription start site of *Cenpf* and promotes growth of HCC in a CENPF‐dependent way {#cas14037-sec-0019}
------------------------------------------------------------------------------------------------------------------------------------

To further address the interaction of LSH with CENPF, we thoroughly analyzed the above ChIP‐seq data. We observed that a specific peak of LSH overlapped at the transcription start site (TSS) of the *cenpf* gene (Figure [5](#cas14037-fig-0005){ref-type="fig"}A), which is located at chr1: 214 776 582‐214 776 968, and verified these results by qPCR using specific primers targeting the TSS region (Figure [5](#cas14037-fig-0005){ref-type="fig"}B). Interaction of LSH with CENPF was further validated in HCC cells. Luciferase activity and CENPF expression were dramatically reduced after LSH expression was inhibited (Figure [5](#cas14037-fig-0005){ref-type="fig"}C‐E). Similarly, luciferase activity and expression of CENPF were obviously increased after LSH was overexpressed (Figure [5](#cas14037-fig-0005){ref-type="fig"}C‐E). However, LSH expression was not significantly changed when CENPF was knocked down (Figure [5](#cas14037-fig-0005){ref-type="fig"}D,E). These results showed that CENPF was one of the downstream targets of LSH. Functional analysis also showed that cell proliferation and migration influenced by LSH overexpression could be partially inhibited by CENPF knockdown (Figure [5](#cas14037-fig-0005){ref-type="fig"}F).

![Lymphoid‐specific helicase (LSH) binds to the transcription start site of *cenpf* and promotes the growth of hepatocellular carcinoma in a centromere protein F (CENPF)‐dependent way. A, ChIP‐seq visualized by UCSC at the *cenpf* gene body and transcription start site (TSS). B, ChIP‐qPCR verified for LSH binding. C, Luciferase activity in the indicated cells. D, Western blot results for LSH and CENPF correlations. E, qPCR results for LSH and CENPF correlations. F, Influence on phenotypes of combined CENPF and LSH. \*\**P* \< 0.01, \*\*\**P* \< 0.001](CAS-110-2133-g005){#cas14037-fig-0005}

4. DISCUSSION {#cas14037-sec-0020}
=============

Lymphoid‐specific helicase plays a critical role in the development of mammals through maintaining DNA methylation and remodeling chromatin.[6](#cas14037-bib-0006){ref-type="ref"}, [7](#cas14037-bib-0007){ref-type="ref"} Recent studies also showed upregulated expression of LSH in several malignant tumors, such as prostate cancer, melanoma, head and neck cancer; and LSH is probably involved in the tumor progression.[12](#cas14037-bib-0012){ref-type="ref"} Moreover, LSH has been reported to be linked to glioma biology as a downstream target of LRP6‐GSK3β‐E2F1 signaling;[19](#cas14037-bib-0019){ref-type="ref"} however, the detailed mechanism of LSH and its downstream targets in cancers still need to be thoroughly addressed. A recent study has reported that by altering nucleosome occupancy at the nucleosome‐free region (NFR) and enhancer, LSH epigenetically suppresses multiple tumor suppressor genes including E‐cadherin, FBP1, IGFBP3, XAF1 and CREB3L3 to promote HCC progression.[20](#cas14037-bib-0020){ref-type="ref"} In the present study, we first showed upregulated expression of LSH in HCC samples from a public database, and established the linkage of high expression of LSH with poor prognosis of HCC patients. Second, we validated these relationships of LSH and prognosis of patients in a larger cohort of HCC patients. Third, we used transfection or interference technology to modify the expression of LSH in HCC cells and found that upregulation of LSH expression in HCC cells promoted growth, migration and invasion in vitro. Last, but not least, the in vivo experiment showed that enforced expression of LSH hastened tumor growth. These data provide sufficient evidence to support the notion that LSH plays a substantial role in the growth and progression of HCC, which is consistent with previous reports of HCC.

Although both we and a previous report found that LSH promotes HCC progression, we have formulated a new explanation for the mechanism.[20](#cas14037-bib-0020){ref-type="ref"} In addition to its role in DNA methylation, LSH is also considered a nucleoprotein. Our important finding from the present study is that LSH plays a key role in tumor growth through regulation of downstream target CENPF. In the present study, we used a combination of mRNA‐seq with ChIP‐seq and confirmed the interaction of LSH and CENPF. qPCR analysis then showed that LSH combined with the *cenpf* TSS area. Importantly, modification of LSH expression in HCC cells could correspondingly alter the expression of CENPF. In turn, alteration of CENPF expression did not influence LSH expression, indicating that CENPF is a downstream target of LSH (summarized in Figure [6](#cas14037-fig-0006){ref-type="fig"}). CENPF protein is a component of the nuclear matrix during the G2 phase of interphase and is required for kinetochore function and chromosome segregation in mitosis. Previous studies have shown that CENPF is upregulated in breast cancer,[21](#cas14037-bib-0021){ref-type="ref"} nasopharyngeal cancer,[22](#cas14037-bib-0022){ref-type="ref"} hepatocellular carcinoma,[23](#cas14037-bib-0023){ref-type="ref"} esophageal squamous cell carcinoma,[24](#cas14037-bib-0024){ref-type="ref"} gastrointestinal stromal tumors[25](#cas14037-bib-0025){ref-type="ref"} and, in some cases it is associated with aggressive tumor phenotype and poor survival.[21](#cas14037-bib-0021){ref-type="ref"}, [22](#cas14037-bib-0022){ref-type="ref"}, [24](#cas14037-bib-0024){ref-type="ref"} However, the mechanism of CENPF expression control remains unclear. In the present study, inhibition of LSH in HCC cells significantly decreased the proportion of cells in G0/G1. More importantly, increased expression of CENPF could rescue the growth, migration and invasion of HCC cells. Clinically, HCC patients expressing high CENPF and LSH showed the poorest prognosis. These data not only broaden our understanding of the mechanism of the role of LSH in tumor progression, but also provide convincing evidence to support the notion that LSH may be a novel therapeutic target for HCC patients.

![Schema of lymphoid‐specific helicase (LSH) regulation of centromere protein F (CENPF) by a protein‐DNA interaction. HCC, hepatocellular carcinoma](CAS-110-2133-g006){#cas14037-fig-0006}

In conclusion, LSH promotes tumor progression through transcription regulation of *cenpf,* and may be an effective therapeutic target for a subgroup of HCC patients with high expression of LSH.

The datasets supporting the conclusions of this article are included within the article and its supplementary material. The datasets used or analyzed during the current study are available from the corresponding author on reasonable request.
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